课题基金 / 基金详情

Full Project 2: Synthesis and MAPK Kinase Inhibitiory Activities in Vitro and In

Full Project 2: Synthesis and MAPK Kinase Inhibitiory Activities in Vitro and In
完整项目 2:体外和体内的合成和 MAPK 激酶抑制活性
批准号:
7250611
负责人:
Samuel R Denmeade
金额:
$8.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2011-08-31

项目摘要

项目成果

Samuel R Denmeade的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Prostate cancer is the most commonly diagnosed cancer in American men. In 2005, an estimated 230,900 new cases will be diagnosed. Although androgen ablation is highly effective palliative therapy, all men eventually relapse due to the presence of androgen independent prostate cancer cells within metastatic sites. Currently there is no therapy that effectively eliminates these androgen independent prostate cancer cells. Identification of the signal transduction pathways responsible for survival and proliferation of androgen independent prostate cancer cells is critical for rational drug development. In preliminary studies, imido-substituted 2-chloro-1,4-naphthoquinones have been identified, that are selective inhibitors of Mek-1. Over the past year approximately 75 napthoquinone analogs have been synthesized and tested for cytotoxicity against a panel of human prostate cancer cell lines. These studies have identified certain structure-cytotoxicity relationships that will be exploited in synthesis of additional analogs. The goal of the studies is to identify potent cytotoxic imido-substituted napthoquinones that will be analyzed for inhibitory activity against MEK-1 and other membrane bound and intracellular protein kinases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate Cancer
  • 批准号:
    10648749
  • 项目类别:
  • 资助金额:
    $22.97万
  • 财政年份:
    2023
  • 负责人:
    Samuel R Denmeade
  • 依托单位:
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response
  • 批准号:
    10366325
  • 项目类别:
  • 资助金额:
    $52.78万
  • 财政年份:
    2021
  • 负责人:
    Samuel R Denmeade
  • 依托单位:
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response
  • 批准号:
    10532225
  • 项目类别:
  • 资助金额:
    $48.86万
  • 财政年份:
    2021
  • 负责人:
    Samuel R Denmeade
  • 依托单位:
Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate Cancer
  • 批准号:
    8669473
  • 项目类别:
  • 资助金额:
    $26.15万
  • 财政年份:
    2014
  • 负责人:
    Samuel R Denmeade
  • 依托单位:
海外基金